Full text is available at the source.
Abstract
Obesity rates continue to rise across Europe, driven by obesogenic environments.
- The rise in obesity is linked to factors such as food systems, urban design, socioeconomic inequalities, and commercial forces.
- Incretin-based medications like GLP-1 receptor agonists have shown significant weight loss and metabolic benefits for individuals.
- There is a concern that the availability of effective treatments may reduce the emphasis on prevention efforts.
- Pharmacotherapy improves individual health outcomes but does not address population-level obesity risk.
- Effective primary prevention is necessary for achieving broader societal, environmental, and economic health benefits.
Simplified